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Abstract
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Objective—Diamond Blackfan anemia (DBA) is a rare inherited bone marrow failure syndrome.
The mainstays of treatment involve chronic red cell transfusions, long-term glucocorticoid therapy,
and stem cell transplantation. Systematic data concerning endocrine function in DBA are limited.
We studied patients in the DBA Registry (DBAR) of North America to assess the prevalence of
various endocrinopathies.
Study design—In a pilot study, retrospective data were collected for 12 patients with DBA.
Subsequently, patients with DBA aged 1–39 years were recruited prospectively. Combined, 57
patients were studied; 38 chronically transfused, 12 glucocorticoid-dependent and 7 in remission.
Data were collected on anthropometric measurements, systematic screening tests of pituitary,
thyroid, parathyroid, adrenal, pancreatic and gonadal function and ferritin levels. Descriptive
statistics were tabulated and group differences assessed.
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Results—Fifty-three percent of patients had ≥ 1 endocrine disorder, including adrenal
insufficiency (32%), hypogonadism (29%), hypothyroidism (14%), growth hormone dysfunction
(7%), diabetes mellitus (2%), and/or diabetes insipidus (2%). Ten of 33 patients with available
heights had height SD <−2. Low 25(OH)D levels were present in 50%. A small proportion also
had osteopenia, osteoporosis or hypercalciuria. Most with adrenal insufficiency were
glucocorticoid-dependent; other endocrinopathies were more common in chronically transfused
patients.
Conclusions—Endocrine dysfunction is common in DBA, as early as the teenage years. While
prevalence is highest in transfused patients, patients taking glucocorticoids or in remission also
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have endocrine dysfunction. Longitudinal studies are needed to better understand the etiology and
true prevalence of these disorders.
Keywords
Hypogonadism; Growth; Vitamin D deficiency; Osteoporosis; Adrenal insufficiency; Iron overload

INTRODUCTION
Diamond Blackfan anemia (DBA), a rare inherited bone marrow failure syndrome affecting
5–7 per million live births per year, is characterized by red cell aplasia, congenital anomalies
and a predisposition to cancer. The most common mutations or deletions involve genes
encoding ribosomal proteins[1–4].

Author Manuscript

The initial treatment is prednisone at a dose of 2 mg/kg/day commencing at 1 year of age,
gradually weaned to ≤ 0.5 mg/kg/day. Although approximately 80% of patients respond to
corticosteroids, only 40% have a sustained response without dose-limiting toxicity. Another
40% are transfusion dependent, requiring packed red cells every 3–4 weeks. Interestingly,
about 20% of patients enter remission, requiring neither glucocorticoids nor transfusions for
≥6 months. Stem cell transplantation is considered in select patients[1].

Author Manuscript

Chronic glucocorticoid therapy predisposes patients to iatrogenic Cushing syndrome and
adrenal insufficiency. Chronic blood transfusions place patients at risk for iron overload of
liver, heart and endocrine organs. Growth failure, osteopenia, diabetes mellitus, and failure
of the thyroid, parathyroids, adrenals, gonads and pituitary gland, may be related to therapy,
and have been described in other hematologic diseases associated with iron overload and in
aplastic anemia[5–8]. Endocrine dysfunction in DBA has only been described in case reports
or small series[9–14]. Due to the rarity of DBA, there are no published systematic studies of
endocrinopathies.
The DBA Registry (DBAR) of North America at the Feinstein Institute for Medical
Research, North Shore-LIJ Health System (NSLIJHS) since 2000, provided an opportunity
for a study of endocrine function in DBA[15]. Our aims were: (a) To study a cross-section of
patients with DBA patients for glucose tolerance, pituitary, adrenal, thyroid, parathyroid and
gonadal function; (b) To estimate the crude prevalence of hormone deficiencies in the DBA
population; and (c) To compare the frequency of endocrine dysfunction in transfusiondependent group to those treated with glucocorticoids or in remission.

Author Manuscript

SUBJECTS AND METHODS
Subjects
We first performed a retrospective chart review of patients enrolled in DBAR evaluated in
the divisions of medical and pediatric endocrinology of NSLIJHS between 1/1/04 and
10/1/12. Twelve patients’ (aged 11–43) charts were reviewed. Subsequently subjects were
recruited prospectively from 12/2012 to 4/2014. Inclusion criteria were: diagnosis of DBA
according to DBAR criteria[1], aged 1–39 years, participating in DBAR, and a) receiving
packed red cell transfusions every 3–4 weeks (at least 15 transfusions); or, b) in remission;
Pediatr Blood Cancer. Author manuscript; available in PMC 2016 April 12.
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or c) glucocorticoid dependent. Exclusion Criteria were: a) pregnancy or b) previous
hematopoietic stem cell transplantation.
Study procedures
The protocol was approved by the NSLIJHS Institutional Review Board. Since the DBAR
includes patients across North America, the principal investigator (PI) discussed consent via
telephone, then sent consent and assent forms and the study questionnaire by mail. Patients
visiting the DBAR at FIMR signed consent in person. Participants completed a short
questionnaire about treatment details and symptoms. Data on clinical history, pubertal stage,
anthropometrics and mid-parental heights were recorded. A broad age range was included
due to the rarity of the disease. Serum ferritin and endocrine test results were collected and
compared with age-appropriate reference standards (Table 1). If indicated, local endocrine
evaluation was recommended.
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Clinical and anthropometric data
Self-reported height and weight data were collected. Body surface area was calculated [16].
Height and weight SD scores were calculated based on Centers for Disease Control (CDC)
2000 standards. Short stature was defined as height SD below −2.0 for age and gender.
Parental heights were used to calculate MPH. BMI was calculated to the nearest 0.1 kg/m2.
For patients under 18 years, BMI was compared to age and gender specific CDC 2000
standards [17]. Adults were classified as normal BMI, overweight (BMI 25–29.9 kg/m2) or
obese (BMI ≥30 kg/m2).
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Patients > 8 years were assessed for pubertal development using tanner staging based on
physical examination within the past year, or based on parent-assessed pubertal development
(breast development in girls; genital enlargement and body hair in boys). Adult patients were
asked if they had received hormone therapy to induce growth or puberty. Puberty was
considered delayed if boys had no signs of pubertal maturation by age 14, or girls had no
breast development by age 13.
Biochemical testing
Laboratory testing was systematically performed between 0700–0800 h after an overnight
fast, prior to a blood transfusion and over two days for subjects under 10 years or weighing
<65 lbs. FSH and LH were measured by immunochromatographic membrane assay (ICMA),
steroid hormones by liquid chromatography followed by tandem mass spectrometry (LCMS/MS)[18,19].

Author Manuscript

Glucocorticoid-treated patients were presumed to have secondary adrenal insufficiency,
unless adequate cortisol response to standard dose cosyntropin, (ACTH 1-24) was
documented. Cosyntropin stimulation tests were performed in subjects with a screening 8
AM cortisol < 16 micrograms/dl[20]. Adrenal insufficiency was classified as symptomatic or
subclinical. Symptomatic adrenal insufficiency was characterized by a subnormal 60 minute
cortisol response following cosyntropin with symptoms of fatigue, hypoglycemia,
hyponatremia, or hyperkalemia. Subclinical adrenal insufficiency was characterized by
biochemical evidence of adrenal insufficiency without symptoms[21] (i.e. 8AM cortisol <5
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micrograms/dL and/or inadequate cortisol rise to stimulation (peak <16 micrograms/dL)
[21]. Mineralocorticoid production was assessed based on published standards for
aldosterone: PRA ratio[22].
GH deficiency was defined by peak level <10 ng/mL in response to two drug stimuli
(arginine + clonidine or glucagon) [23].
The standard calcium - iPTH nomogram was used to interpret parathyroid gland
function[24]. Serum 25(OH)D levels were interpreted as sufficient (>30 ng/mL), insufficient
(20–30 ng/mL), or deficient (<20 ng/mL)[25].
Statistical analysis

Author Manuscript

Results were expressed as median (range) or mean ± 1 SD for continuous variables and
frequencies for categorical variables. ANOVA was used to test the difference between means
of two (t-test) or more groups, and Wilcoxon-signed rank test was used to test the difference
between non-parametric variables. P<0.05 was considered statistically significant. Analyses
were performed using JMP IN 7 software (SAS Institute, Cary, NC).

RESULTS
Patient characteristics (Tables II and III)
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Fifty-seven patients were included, 38 of whom were transfusion-dependent whereas 19
were non-transfusion dependent (seven in remission; 12 glucocorticoid-dependent. (Table
II). Of the total 679 patients in the DBA Registry, 450 patients were eligible. Ninety-two
patients were randomly selected and contacted for recruitment in the prospective study. Of
these 45 patients consented and completed study participation (10% of those eligible). An
attempt was made to obtain complete hormonal profile for all recruited patients; however for
a number of patients for whom data was available in each sub-group was variable for
different endocrine functions (see Table III). All percentages are expressed as a fraction of
the patients with available data and refer to the entire cohort unless otherwise indicated.
Endocrine testing
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Adrenal cortical function—Adrenal insufficiency as defined by the above criteria was
present in 32% of patients (symptomatic: n=2, both transfusion dependent; sub-clinical:
n=14, one patient receiving glucocorticoids and transfusions, one in remission and 12
receiving glucocorticoids). Median prednisone dose for the glucocorticoid-dependent
patients was 3.8 mg/m2/day (range 1.4–15.2). The median hydrocortisone equivalent dose
(calculated using a 1:5 conversion factor) was 18.8 mg/m2/day (range 7–75.8). An
additional 40% (n=20) had low cortisol levels suggestive of adrenal insufficiency, however
confirmatory ACTH stimulation tests were not performed. Of these, 16 patients had
relatively low AM cortisol levels (range: 6.2–12.6 micrograms/dL). Four patients, all
transfusion dependent, had an absolutely low morning cortisol level (<5 micrograms/dL)].
Although 25% of the patients reported salt craving and/or dizziness, none were found to
have mineralocorticoid deficiency. Adrenal androgens (DHEAS and/or androstenedione)
were low for age and pubertal stage in 12% of patients (n=4). This included one patient in
Pediatr Blood Cancer. Author manuscript; available in PMC 2016 April 12.
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remission; the remainder were transfusion dependent. Of the transfused patients, two were
pubertal (age 15.7 years, tanner IV and age 20 years, tanner V) and had normal AM cortisol
level, while the third had no signs of puberty (age 15 years) and a low AM cortisol.
Anterior pituitary function
Seven percent of patients (n=3) had received recombinant human growth hormone (rhGH);
all were male and transfusion-dependent. Two of these patients were treated for GH
deficiency (final height −1.3 SD and −2.3 SD; MPH −0.2 SD for both). The third patient had
normal GH level, but low IGF-1 (<−3 SD for age), short stature (height −2.7 SD) and poor
growth velocity; he was treated for presumed GH resistance. His final height was −3 SD
(poor treatment adherence; MPH −1.3 SD). Additionally, 16% of patients (n=7) had low
IGF-1 or IGFBP-3 levels.
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Height SD was available for 33 patients, of whom 10 had a height <−2 SD (6 transfusiondependent, 2 glucocorticoid-dependent, 2 in remission). Both patient and mid-parental
height SD values were available for 28 patients. Of these, 64% had a height SD of −1 below
their MPH.
BMI could be calculated for 31 patients. Of these, 10% were underweight (n=3), 29%
overweight (n=9) and 19% obese (n=6). The relative proportion of overweight and obese
individuals was highest in the transfusion-dependent patients.
Posterior pituitary function
Diabetes insipidus (DI) was diagnosed in a single 16.5-year-old transfusion-dependent
patient.
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Glycemic control
The diagnosis of diabetes mellitus was made in one 14.5-year-old transfusion-dependent
patient who presented with symptoms of hyperglycemia. Screening fructosamine levels,
when available, were normal in all other patients.
Thyroid function
Hypothyroidism was reported in 14% of the patients (n=8, all transfusion-dependent). Four
additional patients had mildly elevated TSH (range: 4.98–9.36 μIu/ml) and normal T4 ; and
one asymptomatic glucocorticoid-dependent patient had a low free T4 with a low-normal
TSH. Calcium metabolism, parathyroid function and Vitamin D.
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Two patients had probable hypoparathyroidism (low calcium with inappropriately normal
iPTH level), though none reported symptoms of hypocalcemia. One patient taking calcium
supplements was hypercalcemic with a normal iPTH level. Approximately 28% of patients
were taking supplemental vitamin D. Overall, 33% of patients (n=17) had insufficient
25(OH)D levels; 24% (n=12) were vitamin D deficient including some on supplemental
vitamin D. Though data was not prospectively collected for urine calcium excretion,
hypercalciuria (elevated spot or 24 hour urine calcium: creatinine ratio) and/or kidney stones
were reported by 7% of the patients (n=4, ages 11.6–30.3 years, while three of these were
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transfusion-dependent and receiving chelation with deferasirox, the fourth patient was
receiving both glucocorticoids and transfusions and chelation with deferoxamine). Vitamin
25(OH)D levels on these patients were in the low-normal range; three had a family history
of kidney stones.

Author Manuscript

Data for bone density was not prospectively collected, however osteoporosis was reported in
4 patients: three adults (aged 27–34.9; 2 males, 1 female) and one male child (age 11.6), all
transfusion-dependent. [26] All had BMD ≤ −2 SD. The child also had multiple vertebral
compression fractures (children diagnosed based on most recent densitometry guidelines
[26]). Three additional patients had adverse skeletal outcomes that developed during
glucocorticoid therapy (ages 10.4–20, including a hairline leg fracture and avascular necrosis
of the femoral neck). Osteopenia was reported in another 2 patients: a 19-year-old
glucocorticoid-dependent female and 21-year-old male treated with glucocorticoids and
transfusions.
Gonadal function
Among children >8 years and adults, hypogonadism was present in 29% of patients (n=10),
three of whom were not previously diagnosed. All were diagnosed at ≥ 14.4 years of age and
were transfusion-dependent. The male to female ratio was 8:2 (diagnosed at or after 14.4
years). Considering age cut-offs for delayed puberty (Table 1), 47% of males >14 years had
hypogonadism, while only 15% of females >13 years had hypogonadism. None of the
patients attempted pregnancy during the study.
Iron overload

Author Manuscript

Ferritin levels were available for 46 patients, 80% of which (n=37) were above respective
reference ranges [median 1141 ng/mL (range 214 – 5993)]. Of these 37 patients, most were
chronically transfused, four were glucocorticoid-dependent and one was in remission. The
ferritin level for the glucocorticoid dependent patients ranged from 330 – 689 ng/mL (last
transfused 11 months to 7 years prior to this study). The ferritin level for the patient in
remission was 1993 ng/mL (last transfusion 30 years earlier). On further investigation this
patient was found to be homozygous for the C282Y mutation in the HFE gene, indicating
primary hemochromatosis. There were insufficient liver iron concentration data by MRI to
quantitate iron burden. Therefore, statistical analysis of the relationship between iron burden
and endocrine abnormalities could not be performed.

DISCUSSION
Author Manuscript

Our report evaluates endocrine function in patients with DBA treated with transfusions or
glucocorticoids and those in remission. We found a considerably higher incidence of
endocrinopathies than previously reported. In our cohort, 53% of patients had one or more
endocrinopathies (not including vitamin D deficiency/insufficiency). In order of frequency,
these included adrenal insufficiency, hypogonadism, hypothyroidism, growth hormone
deficiency/resistance, diabetes mellitus and diabetes insipidus (Figure 1).
Osteoporosis/osteopenia and hypercalciuria were also reported by history, although primary
data were not uniformly available. Published reports from European DBA registries have
Pediatr Blood Cancer. Author manuscript; available in PMC 2016 April 12.
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focused primarily on chronically transfused patients[9–13]. In the Italian cohort, 23% of
patients (7 of 31, median age 9.2 years, range 1.8–29.6) had one or more iron-related
endocrine or other organ complications. In the French cohort, ~14% of patients (13 of 95,
mean age 13.5 ± 10.4 years) had endocrinopathies; few iron overloaded transfused patients
were tested. In both reports, hypothyroidism was most frequent, followed by
hypogonadism[12,13]. Amongst our chronically transfused patients, 45% (17 of 38) had one
or more endocrinopathies, likely due to their older age (median age 17.4 years, range 2.3–
43), and because screening was done irrespective of symptoms or degree of iron overload.
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In our study, patients underwent their first endocrine evaluation anywhere from 1.5 to 30.6
years after DBA diagnosis, with glucocorticoid-dependent patients among the earliest
evaluated. The median interval from diagnosis to first endocrine evaluation was 3.5 years for
those patients who were corticosteroid-dependent, 4.5 years for those in remission, and 8.3
years for transfusion-dependent patients. This is noteworthy, as high transfusion burden was
most often associated with endocrinopathies. Approximately 33% of all patients indicated
that they had never undergone a prior endocrine evaluation. While the age at diagnosis of
pre-existing endocrinopathies was not uniformly captured in our study, for the few patients
that this information was available, the age at diagnosis of a first endocrinopathy ranged
from 13.5–19 years. This does not include glucocorticoid-dependent patients with presumed
iatrogenic adrenal insufficiency.
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Adrenal insufficiency was the most common endocrinopathy in our cohort: 32%, including
all glucocorticoid-dependent patients who were presumed to have secondary adrenal
insufficiency by the virtue of treatment with prolonged or supraphysiologic doses. Although
less common, sub-normal cortisol response was also seen in patients receiving transfusions
(9%) or in remission (20%). The etiology of adrenal insufficiency in the latter groups was
unclear; we postulate that this may be related to prior transfusions. In comparison,
subclinical adrenal insufficiency has been reported in 13–46% of beta-thalassemia
patients[27,28]. Sources of variability include the test methodology and cortisol cut-off used.
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Hypogonadism in patients >8 years age was the second most common endocrinopathy in our
cohort (29%; M:F ratio =3:1), all from the transfusion-dependent group. Clinical
presentations included failure to initiate puberty, arrest of puberty, and loss of libido or
sexual function after puberty. Prior studies in patients with DBA have reported a
hypogonadism prevalence of 8–13%, somewhat lower than our study[12,13]. The reported
prevalence in beta-thalassemia patients ranges from 32–55%, increasing with age[5,29,30].
Pituitary iron overload in transfusion dependent patients with thalassemia and DBA can
begin in the first decade of life, but clinically significant pituitary volume loss occursin the
second decade[31]. At least half the patients with hypogonadism in our cohort had central
hypogonadism, suggesting pituitary or hypothalamic iron overload.
Hypothyroidism has been previously reported in 3% and 16 % of patients with DBA in the
Italian and French cohorts, respectively[12,13]. This is similar to our findings of 14% in our
whole cohort and 22% of transfused patients. In comparison, prevalence of hypothyroidism
in the beta-thalassemia population was found to be 8.7% (range 0–18%)[5], depending on
the number and age of subjects.
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Of our patients with available height measurements, 30% had short stature, similar to that
reported from the French DBA registry[12] and to the 25–31% for patients with betathalassemia[5,29]. Of our patients, 60% had heights > 1 SD below MPH. Short stature in
DBA patients may be associated with skeletal malformations, type of treatment and iron
overload status[12,32]. Data on skeletal malformations were not collected in our study.
Three patients in our study received rhGH therapy. There have been reports of positive
outcomes using growth hormone for both growth hormone deficiency and resistance in
patients with DBA [11,12,33]. A recently published retrospective report on rhGH therapy in
patients with DBA showed significant increases in height velocity up to two years and height
Z-scores up to four years after starting GH therapy. Adult heights were not obtained. Of
note, in this study, the baseline peak stimulated GH level for the treated patients was
11.5±10.6 ng/mL indicating that only some were GH deficient based on the most liberal cutoff of 10 ng/mL[34]. The association of DBA and various malignancies, especially
osteosarcoma[15,35], raises theoretical concerns about GH safety that must be explained to
the patient and family. GH treatment should be monitored by maintaining serum IGF1 in the
mid-normal range for age.
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Vitamin D insufficiency and deficiency were common in our cohort, with 57% having a
25(OH)D level below 30 ng/mL (75 nmol/L), despite some taking supplements. This
proportion is somewhat lower than estimates in the general population and beta-thalassemia
patients[5,36]. These findings suggest that either supplemental doses of vitamin D were
inadequate or that patients were not adherent to the prescribed regimen. Chronic transfusions
and associated co-morbidities are known risk factors for fractures, reported in up to 36% of
patients with thalassemia[37]. Osteopenia, osteoporosis and/or fragility fractures were
reported in a minority of our patients (n=9), though the information was based on self-report
only and bone density data were not uniformly available. Hypercalciuria, nephrocalcinosis
and/or kidney stones were present in 4 patients. Among the risk factors for nephrolithiasis
were treatment with deferasirox[38] and a family history of kidney stones. Although
hypercalciuria has been described in up to 21% of patients with beta-thalassemia, perhaps
due to deferasirox [5,38], this was a new finding in patients with DBA.
While diabetes mellitus developed in only one transfusion-dependent patient at age 14.5, it
has been described in both transfusion-dependent and glucocorticoid-dependent
patients[13,14]. It appears to be less frequent in DBA than in beta-thalassemia (14.1%)[5].
The best screening test for diabetes in transfusion-dependent patients is controversial. One
recent study in thalassemia patients found continuous glucose monitoring promising[39].

Author Manuscript

One patient with panhypopituitarism due to iron overload developed diabetes insipidus,
another finding not previously reported in DBA. Symptomatic hypoparathyroidism was not
diagnosed, although it was suspected in two patients and has been described[12,13].
Ferritin is not a reliable marker of iron burden or the chronicity of iron overload. Hence,
statistical correlation between iron burden and the presence of endocrinopathies was not
performed.
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Intrinsic limitations of our study include the small population due to the rarity of DBA, the
cross-sectional nature of data collection, and geographic distance from the study center for
the majority of DBAR patients. Other limitations were the relative young median age of our
patients, self-reported parental heights, growth measurements and pubertal stage for several
patients, assays done in different laboratories and the lack of data on hepatic and cardiac
MRIs as measures of iron burden. Due to the small number of patients in remission, the
study was not adequately powered to exclude a contributing effect of DBA itself on any of
the endocrine diagnoses. Despite these limitations, this study is unique in that it evaluated
endocrine dysfunction in a large DBA cohort, both children and adults, regardless of mode
of treatment, and has thus improved our knowledge in this field.
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In summary, over half of the studied DBA patients (53%) had one or more endocrinopathies,
several beginning in childhood. While most of these were present in transfused patients,
glucocorticoid-dependent patients and those in remission also showed endocrine
dysfunction. Based on our experience, we make the following suggestions regarding
endocrine screening of DBA patients:

Author Manuscript
Author Manuscript

1.

Graphing height and weight should be done in children and adolescents every 6–12
months to timely diagnose growth failure. BMI should also be monitored.

2.

Screening for gonadal insufficiency should be considered in all transfused patients
with delayed puberty, cessation of pubertal progression, or loss of libido or sexual
function in adults.

3.

Hypothyroidism screening should be considered in all DBA patients irrespective of
treatment type or remission state after age 14.

4.

Periodic screening by early morning serum cortisol measurement is suggested in
iron overloaded patients, and cosyntropin testing in patients after discontinuation of
glucocorticoids to ensure normal adrenal function.

5.

Vitamin D supplementation should be given to maintain 25(OH)D levels above 30
ng/mL (75 nmol/L). Consider screening urine calcium:creatinine ratio annually for
hypercalciuria. Periodic bone density measurements should begin in late childhood.

6.

Annual screening for diabetes mellitus should begin by age 14. HbA1c may be used
to screen non-transfused patients, with fructosamine or oral glucose tolerance test
in transfused patients. Screening for diabetes insipidus should also be considered in
symptomatic patients.

7.

Since prevalence of endocrinopathies tends to increase with age, normal screening
labs at any age should not preclude lifetime monitoring of these patients. Timely
diagnosis and treatment may serve to avoid further morbidities.
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DBA

Diamond Blackfan Anemia

DBAR

Diamond Blackfan Anemia Registry

SD

Standard deviation

IGF-1

Insulin-like growth factor 1

IGFBP-3

Insulin-like growth factor binding protein 3

TSH

Thyroid stimulating hormone

T4

Thyroxine

iPTH

Intact parathyroid hormone

25(OH)D

25-hydroxy vitamin D

ACTH

Adrenocorticotrophic hormone

PRA

Plasma renin activity

DHEAS

Dehydroepiandrosterone sulphate

LH

Luteinizing hormone

FSH

Follicular stimulating hormone

SHBG

Sex hormone binding globulin

HbA1c

Hemoglobin A1c

GH

Growth hormone

MPH

Midparental height

rhGH

Recombinant human growth hormone

DI

Diabetes insipidus
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Figure 1. Endocrine dysfunction in patients with Diamond Blackfan Anemia

Bar diagram showing frequencies of various endocrine dysfunction in our patients with
Diamond Blackfan anemia
* This includes all patients with 25(OH)D levels <20 ng/mL and 20–30 ng/mL
** Most of these patients were receiving chronic glucocorticoid therapy and had presumed
secondary adrenal insufficiency.
*** Other endocrinopathies including diabetes mellitus, diabetes insipidus, osteoporosis,
osteopenia and hypercalciuria were present in a minority of patients
#Total number of patients evaluated for each endocrinopathy somewhat varied as detailed in
Table III.
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Table I

Author Manuscript

Test results collected for evaluation of function of various endocrine glands

Author Manuscript

Endocrine gland

Tests

Anterior pituitary gland*

insulin-like growth factor-1 (IGF-1), insulin-like growth factor binding protein-3
(IGFBP-3), prolactin

Posterior pituitary gland

serum and urine osmolality

Thyroid gland

thyroid stimulating hormone (TSH), total and free T4

Parathyroid gland and vitamin D metabolism

calcium, intact parathyroid hormone (iPTH), 25-OH-vitamin D [25(OH)D]

Adrenal cortex: glucocorticoid synthesis

AM Cortisol

Adrenal cortex: mineralocorticoid synthesis

plasma renin activity (PRA), aldosterone

Adrenal cortex: sex steroid synthesis

androstenedione, dehydroepiandrosterone sulphate (DHEAS)

Pancreatic endocrine function/glucose metabolism**

fructosamine (or HbAlc in non-transfused patients)

Gonadal function for ages ≥ 8 years#

luteinizing hormone (LH), follicle stimulating hormone (FSH), testosterone and sex
hormone binding globulin (SHBG) (in males); and estradiol (in females).

*

Additional tests for evaluation of other pituitary hormones are mentioned along with the respective endocrine glands they regulate.

**
HbA1c value >6.5% as per ADA guidelines used to screen for diabetes mellitus in non-transfused patients, but not: as reliable in patients
transfused frequently. Fasting and post-prandial glucose can provide a good measure of glycemic control in transfused patients, but was not feasible
to obtain due to the design of study. Fructosamine used as a screen for short-term glycemic control and some studies show correlation between
fasting glucose and fructosamine level. However no definitive fructosamine level is considered diagnostic for diabetes and patients with values
outside laboratory reference range need further evaluation.
#

Patients on sex hormone replacement with a history of delayed puberty (defined as no breast development in girls >13 years and no testicular
enlargement in boys >14 years) are considered to have hypogonadism. Additionally, patients with elevated FSH and/or LH with or without low sex
hormones are considered to have primary hypogonadism. Secondary hypogonadism diagnosed in patients with low LH and/or FSH and sex
hormones with evidence of other pituitary hormone deficiencies; those with history of hypogonadism and on treatment with human chorionic
gonadotropins (HCG) or in males on long term androgen therapy for anemia.
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Table II

Author Manuscript

Patient Characteristics
Parameter

Overall

On Chronic Transfusions

Glucocorticoid-dependent

Remission*

n

57

38

12

7

Age (in years) at endocrine
evaluation€

14.4 (2–43)

17.4 (2.2–43)§

10.5 (2–30.7)

12.9 (3–33.2)

Males (%)

56

58

50

57

Height SDS#€

−1.1 (−3.2 to 1.7)

−1.1 (−3.2 to 0.1)

−1.3 (−2.4 to 0.4)

−0.6 (−2.6 to 1.7)

Difference between subject’s height
SDS and MPH height SDS€¥

−1.2 (−4.6 to 0.6)

−1.2 (−4.6 to 0.3)

−0.6 (−2.3 to 0.6)

−1.2 (−1.6 to −1.0)

€

Expressed as Median (range).

§

< 0.05 for DBA transfused group versus glucocorticoid-dependent group.

Author Manuscript

*

Duration of remission >2 years (range 2–28 years) in all subjects except for 1 patient (6 months).

#

Height SDS data available for 33 DBA patients (n=19, 10 and 4 respectively in chronic transfusion, glucocorticoid-dependent and remission
groups).

¥

Both patient and mid parental height SDS data were available for 28 DBA patients (n=19, 5 and 4 respectively in chronic transfusion,
glucocorticoid-dependent and remission groups).
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Table III

Author Manuscript

Table showing frequencies of various endocrinopathies in patients with Diamond Blackfan anemia

Author Manuscript

Overall*

On chronic Transfusions*

Glucocorticoid-dependent*

Remission*

Patients with endocrinopathies
a) None
b) One only
c) Two only
d) Three only
e) Greater than
three
f) Indeterminate screening labs

a) 30% (17/57)
b) 37% (21/57)
c) 10% (6/57)
d) 4% (2/57)
e) 2% (1/57)
f) 17% (10/57)

a) 34% (13/38)
b) 26% (10/38)
c) 11% (4/38)
d) 5% (2/38)
e) 3% (l/38)
f) 21% (8/38)

a) 0/12
b) 83% (10/12)
c) 17% (2/12)
d) 0/12
e) 0/12
f) 0/12

a) 57% (4/7)
b) 14% (l/7)
c) 0/7
d) 0/7
e) 0/7
f) 29%(2/7)

Adrenal insufficiency (for glucocorticoids)
a) Symptomatic
b) Subclinical

a) 4% (2/50)
b) 28% (14/50)

a) 6% (2/33)
b) 3% (1/33)

a) 0/12
b) 100% (12/12)

a) 0/5
b) 20% (1/5)

Mineralocorticoid insufficiency

0/30

0/19

0/8

0/3

Adrenal Sex steroid insufficiency

12% (4/32)

12% (3/24)

0/5

33% (1/3)

Growth hormone dysfunction

7% (3/45)

10% (3/30)

0/10

0/5

Diabetes insipidus

2% (1/39)

4% (1/27)

0/9

0/3

Hypothyroidism

14% (8/55)

22% (8/36)

0/12

0/7

Diabetes mellitus

2% (1/40)

4% (1/28)

0/9

0/3

Ca-iPTH abnormalities
a) Probable Hypoparathyroid ism
b) Hypercalcemia with normal iPTH

a) 4% (2/46)
b) 2% (1/46)

a) 3% (1/31)
b) 0/31

a) 10% (1/10)
b) 10% (1/10)

a) 0/5
b) 0/5

Vitamin D
a) insufficiency
b) deficiency

a) 33% (17/51)
b) 24% (12/51)

a) 35% (12/34)
b) 26% (9/34)

a) 27% (3/11)
b) 9% (1/11)

a) 33% (2/6)
b) 33% (2/6)

Hypogonadism (among children >8 years
and adults)

29% (10/34)

40% (10/25)

0/5

0/4

Iron overload

80% (37/46)

97% (32/33)

40% (4/10)

33% (1/3)

*

Author Manuscript

Data expressed as: Percentage of patients with the disorder (number of patients with the disorder/number of patients for whom data was available)
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